Honasa Consumer is an Indian beauty and personal care platform with a portfolio spanning skincare, haircare, and men's grooming. Its core brands are Mamaearth and The Derma Co, supplemented by younger brands like Aqualogica, Dr. Sheth's, B Blunt, and Reginald Men (acquired in January 2026). The company sells through e-commerce, quick commerce, modern trade, and a direct general trade network that covers roughly 250,000 outlets. In Q1 FY27 (quarter ending June 2026), Honasa reported ₹110 crore EBITDA and ₹90 crore PAT on 30.5% volume growth, while maintaining negative working capital. The business earns a gross margin of 71.9% (Q2 FY26) and an EBITDA margin of 11.3% in Q4 FY26, with management targeting 15% EBITDA margin within five years. This margin profile, combined with leading positions such as Derma Co being the #1 sunscreen brand in India (Euromonitor) and Mamaearth gaining 350 bps share in face washes and 160 bps in shampoos (Nielsen, Aug 2026 call), places Honasa well above the typical consumer goods commodity threshold.
The economics persist because of a rare combination of brand-building capabilities and distribution control. Honasa has demonstrated the ability to create large brands from scratch: Mamaearth crossed ₹1,000 crore, and Derma Co followed within a few years, reaching ₹1,000 crore ARR by August 2026 after being at ₹750 crore in November 2025. The company's digital-first content engine and heavy R&D investment—exemplified by Ficin, a patent-protected 12-hour fragrance elixir, and Derma Co's in vivo tested sunscreens—create switching costs that legacy players cannot easily replicate. Its direct distribution network, covering top 100 cities with inventory under 30 days, allows efficient scale and a negative working capital cycle. Furthermore, the company's disciplined focus on core categories (face wash, shampoo, sunscreen), which now comprise ~85% of Mamaearth's sales, drives repeat purchases. These barriers are evidenced by consistent share gains even as large FMCG competitors increase online presence.
The inflection is already underway. By August 2026, Derma Co crossed ₹1,000 crore ARR, while Mamaearth's next milestone is ₹1,500 crore (stated in November 2025). Management targets expanding Mamaearth's distribution from 200,000 to 500,000 outlets over the next 3-5 years (May 2026 call), which would materially lift reach. Reginald Men, acquired in January 2026, has an ARR of ₹150 crore and is projected to reach ₹500 crore in 4-5 years. The company also launched Ficin, a fragrance brand, in Q1 FY27 and is building Honasa Health for nutraceuticals, with the Fluence acquisition in progress. On margins, FY26 EBITDA margin was 9.3%, and management guides 150-200 bps improvement in FY27, implying FY28 margins in the 12-13% range if the 100-150 bps annual improvement continues. Revenue growth is expected to exceed the high-teens CAGR commitment, so by mid-2028 the company's annual run-rate could be ₹3,700-4,000 crore, based on the Q4 FY26 exit of ₹682 crore and sustained 20% growth.
Management has walked the talk consistently. In August 2025, they guided double-digit value growth for FY26 and a 7% EBITDA margin; by February 2026, they reported 21.7% revenue growth and 10.9% EBITDA, beating both targets. They committed to 100-150 bps annual margin expansion and 50,000 new GT outlets—both were reiterated as on-track (database fallback). In May 2026, they declared a first dividend of ₹3 per share (about 50% of FY26 PAT), while maintaining negative working capital and generating cash. The latest call (August 2026) showed Q1 FY27 EBITDA of ₹110 crore, up from FY26's quarterly average of ~₹65 crore, and they reaffirmed the 15% EBITDA margin target with 100-150 bps annual improvement across five years. No guidance cuts or misses have occurred; in fact, the company upgraded its specificity by naming Derma Co at ₹1,000 crore ARR and Mamaearth at double-digit CAGR. This record of met commitments supports confidence in the forward path.
Earnings visibility is high. From FY26 EBITDA margin of 9.3%, the path to 15% by the end of five years implies roughly 100-150 bps annual improvement; the company has already delivered 300-350 bps in Q1 FY27 from mix and operating leverage, though that included seasonality and one-time benefits that will fade in Q2. The kill shot to watch is crude oil/packaging inflation, which management flagged for Q2 FY27 and is offsetting with calibrated price increases. The other key falsifier is whether young brands like Aqualogica and Dr. Sheth's can scale beyond the ₹150-200 crore ARR plateau that has historically been a challenge (Aug 2026 call). If Derma Co's growth decelerates or Mamaearth fails to maintain double-digit growth, the high-teens CAGR would be at risk. The tension between reported growth and like-to-like growth from the Flipkart settlement adjustment will resolve from Q2 FY27, making comparisons clean. Overall, the business is a compounder with proven execution and a clear margin expansion trajectory.
companyname: Honasa Consumer Limited ticker: HONASA sector: Beauty and Personal Care (BPC) / FMCG Honasa Consumer Limited is a digital-first house of brands in the Indian Beauty and Personal Care (BPC) sector. It was founded in 2016, is headquartered in Gurugram, and builds and scales purpose-driven brands across skincare, haircare, baby care and colour cosmetics (FY25 Annual Report). The company describes itself as "India's leading digital-first player in the Beauty and Personal Care (BPC) sec...
Read the full report →margin expansion, market share gain
Mamaearth brand guided at double-digit CAGR over next 5 years driven by share gain in focus categories and distribution expansion to 500,000 outlets
Guidance upgradedconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Honasa Consumer Limited and 4,900+ companies.
5-day free pass. No card required.